PT Darya-Varia Laboratoria Tbk (DVLA.JK) Stock

DVLA.JK logo

PT Darya-Varia Laboratoria Tbk

DVLA.JKIndonesia
Healthcare

Company profile

PT Darya-Varia Laboratoria Tbk reported revenue of 2.23 trillion IDR for fiscal year 2025, up 6.9% from fiscal year 2024, and net income of 163.95 billion IDR. That is a net profit margin of 7.3% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 594.80 billion IDR, up 9.3% from a year before. Its largest business segment, Consumer Health Products, brought in 56% of segment revenue in fiscal year 2025; Indonesia was the largest region with 90%. In Q1 2026 it reported net income of 55.31 billion IDR, against net income of 78.87 billion IDR a year earlier. Our analysis of its filings shows revenue growing from 1.89 trillion IDR in fiscal year 2023 to 2.23 trillion IDR in fiscal year 2025, 8.6% a year on average. PT Darya-Varia Laboratoria Tbk reports about 1,344 full-time employees.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About PT Darya-Varia Laboratoria Tbk

PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Consumer Health Products, Prescription Drugs, Export & Toll Manufacturing, and Services. The company offers consumer health products, including skin nutrition products under the Natur-E brand; respiratory products under the Decolgen, ALLERIN EXPECTORANT, Decolsin, NEOZEP, STOP COLD, SILEX, and HERBABLEND brands for nasal congestion, cough, and breathing issues caused by allergy; multivitamins under the Enervon-C, Enervon Active, Enervon Gold, and Supertin brands; vitamin C under the Vicee brand; supplement for kids with Zinc and vitamin C under the Imunped brand; Biogesic for various types of pain; Diatabs, a anti diarrhea product; and New Enzyplex to prevent indigestion. It also provides prescription products for various therapeutic areas, including cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotic, women healthcare, antiparasit, vitamin and food supplements, anti fungal, plastic surgery, general surgery, burn, trauma wound, aesthetic medicine, somatik, ear healthcare, and central nerve systems. In addition, the company offers toll manufacturing services for soft gelatin capsules, as well as sterile injections and low volume solid products. It also exports its products. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk operates as a subsidiary of Blue Sphere Singapore Pte. Ltd.

Largest shareholders

  • United Laboratories, Inc.92.12%

Share of the company, as of September 25, 2026

Leadership

  • Ian Martin Wibawa Kloer — President Director, 51
  • Celso Paz Lim — Finance Director & Director, 56
  • Widya Olivia Tobing — Head of Legal & Corporate Affairs Division and Corporate Secretary, 49
  • Dandan Darmawan — Director of Human Resources Development
  • Chandra Ngesahkan Halomoan Tarigan — Head of Internal Audit Unit, 46

How much revenue does PT Darya-Varia Laboratoria Tbk make?

PT Darya-Varia Laboratoria Tbk reported 2.23 trillion IDR in revenue for fiscal year 2025, up 6.9% from 2.09 trillion IDR in fiscal year 2024. In Q1 2026 revenue was 594.80 billion IDR.

What is PT Darya-Varia Laboratoria Tbk's largest business segment?

Consumer Health Products, with 1.26 trillion IDR or 56% of segment revenue in fiscal year 2025. Next: Prescription Drugs (30%) and Export & Toll Manufacturing (12%).

Where does PT Darya-Varia Laboratoria Tbk make most of its revenue?

Indonesia: 90% of revenue by region in fiscal year 2025, followed by Export (10%).

What companies are similar to PT Darya-Varia Laboratoria Tbk?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Kalbe Farma Tbk. (KLBF.JK), PT Tempo Scan Pacific Tbk (TSPC.JK), PT Pyridam Farma Tbk (PYFA.JK), PT Merck Tbk (MERK.JK).

How has PT Darya-Varia Laboratoria Tbk's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 1.90 trillion IDR; FY2022, 1.92 trillion IDR; FY2023, 1.89 trillion IDR; FY2024, 2.09 trillion IDR; FY2025, 2.23 trillion IDR.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees1,344
FoundedJan 1, 1976
IPO DateNov 11, 1994
IPO StatusPublic
HeadquartersJakarta, Indonesia
ExchangeJakarta
TimezoneAsia/Jakarta (WIB)

Contact & Links

Address
Tower C, Jakarta, 12430
Phone
62 21 227 68000
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “PT Darya-Varia Laboratoria Tbk (DVLA.JK)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/DVLA.JK

LinkedInLinkedInXXYouTubeYouTube